DANA-FARBER CANCER INSTITUTE
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Exercise Intervention in Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Behavioral: Moderate-Intensity Exercise
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 101
- Registration Number
- NCT00405782
- Locations
- πΊπΈ
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Neoplasms
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00402545
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Drug/Agent Toxicity by Tissue/OrganLeukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: pegaspargaseDrug: methylprednisoloneDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- π¨π¦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
πΊπΈHerbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
π¨π¦Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
- Conditions
- Esophageal CancerStomach Cancer
- Interventions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT00394433
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Rituximab for Prevention of Chronic GVHD
- Conditions
- Hematological Malignancies
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 65
- Registration Number
- NCT00379587
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 65
- Registration Number
- NCT00378209
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 68
- Registration Number
- NCT00378105
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: anti-thymocyte globulinBiological: peripheral blood lymphocyte therapyDrug: fludarabine phosphateDrug: methylprednisoloneDrug: thiotepaProcedure: allogeneic hematopoietic stem cell transplantationProcedure: in vitro-treated peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00376480
- Locations
- πΊπΈ
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
πΊπΈUniversity of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
- Conditions
- Hematologic Malignancies
- Interventions
- Drug: Bortezomib (Velcade)Drug: TacrolimusDrug: MethotrexateProcedure: blood stem cell transplantation
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT00369226
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈBrigham and Women's Hospital, Boston, Massachusetts, United States
Ph II CHOP+Velcade in Mediastinal LBCL
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00361621
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States